Navigation Links
Gentiva(R) Health Services Announces Fourth Quarter and Fiscal 2007 Results, and Raises 2008 Outlook
Date:2/14/2008

porate expenses, depreciation, amortization, and

interest expense (net), but include revenues and all other costs

directly attributable to the specific segment.

2) Fiscal 2006 results included approximately $1.9 million recorded and

received from the total settlement of $5.5 million relating to the

Company's appeal filed with the U.S. Provider Reimbursement Review

Board ("PRRB") on the reopening of all of its 1999 cost reports.

3) Corporate expenses for the fourth quarter and fiscal 2007 included a

credit of $0.8 million relating to an adjustment of remaining lease

obligations associated with a 2002 restructuring plan and a net charge

of $1.1 million relating to miscellaneous adjustments. Corporate

expenses for the fourth quarter and fiscal 2006 included a credit of

approximately $0.9 million relating to legal settlements.

4) EBITDA, a non-GAAP financial measure, is defined as income before

interest expense (net of interest income), income taxes, depreciation

and amortization. Management uses EBITDA to evaluate overall

performance and compare current operating results with other companies

in the healthcare industry. EBITDA should not be considered in

isolation or as a substitute for net income, operating income or cash

flow statement data determined in accordance with accounting

principles generally accepted in the United States. Because EBITDA is

not a measure of financial performance under accounting principles

generally accepted in the United States and is susceptible to varying

calculations, it may not be comparable to similarly titled measures in

other companies.

5) EBITDA included equity-based compensation expense for the fourth

quarters of 2007 and 2006 of approximately $1.7 million and $1.3

million, r
'/>"/>

SOURCE Gentiva Health Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Gentiva(R) Health Services and CIGNA HealthCare Extend National Homecare Contract Through January 31, 2011
2. Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi
3. Gentiva(R) Health Services Promotes Boelsen to Senior Vice President, CareCentrix(R)
4. Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco
5. Gentiva(R) Health Services to Present November 7 at CIBC Healthcare Conference in New York
6. Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007
7. Gentiva(R) Health Services Files Universal Shelf Registration Statement
8. XTend Medical (XMDC) Begins Remote Diabetic Telehealth Program
9. Underserved Women and Children in Oakland County Get Big Boost for Free Health Care from Chrysler 300C Lease Giveaway
10. AIDS Action Asks Mass. Public Health Council to Forge a State AIDS Plan to Help Stop HIV/AIDS Here
11. Is a Common Cold a Serious Health Condition?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...Late recurrence is a risk for some pediatric cance...central nervous system, according to a new study p...National Cancer Institute . , This study was und...recurrence (after 5 years and up to 20 years) for ...sker, M.D., of the Aflac Cancer Center and Blood D...
(Date:12/4/2009)...Case Western Reserve University researchers, from ...discovered two new metabolic pathways by which pro...e, known as 4-hydroxyacids, are metabolized. The p...lomics and mass isotopomer analysis. The findings ...rug of abuse gamma-hydroxybutyrate, also known as ...
(Date:12/4/2009)... Dental tourism is a phenom...for an alternative to the high price of dental wor... search for lower priced dental care, people have ...ce as a dental tourist destination. , ...ng in business for more than 6 years, Mexican Dent...
(Date:12/4/2009)...ve a response to pressure from federal regulators ... , FRIDAY, Dec. 4 (HealthDay News) -- The ma...riday presented federal regulators with plans to c...rmaceutical companies have been under pressure fro...ind a way to stop the hundreds of fatal overdoses ...
(Date:12/4/2009)...search and surveillance urged for at-risk patient ...s) -- Some childhood cancers, particularly Ewing s...he risk of late recurrence, U.S. researchers have ...2,795 five-year survivors of the most common pedia...ncer Survivor Study. , The researchers found th...
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2
...e of Fayette,County,s largest employers will expan...of an $8.4 million, 20-year investment by the comm...,000 grant each year through the,Fayette County Re...uction of a new,inpatient tower that will hold 56 ...
...ants for Families and Honors for Corporate Suppor...ies Affected, GURNEE, Ill., Nov. 5 This year you...oney for pediatric cancer research and,families of...uper hero costumes at this year,s Super Jake Found...
...Heart,Association and its Pharmaceutical Roundtabl...he Outcomes Research Centers initiative. The proje...troke research focusing on,the end results, or out...eart Association national board member David Spina...
...agni, President,and CEO of America,s Health Insura...ment congratulating President-elect Barack Obama:,...r his historic victory,last night. Now is the time... care challenges facing the nation. We,support cov...
...he American,Nurses Association (ANA) congratulates...tory, and looks forward to working with the new ad...change for nurses and the patients we,serve., Pre...wn a commitment to advancing the nursing professio...
...ward to health system reform in 2009, WASHINGTON,...lsen, M.D., AMA President:, "The American Medical...Obama on his successful bid for the presidency of ... President-elect Obama,s focus on expanding health...
Other Medicine News:Health News:State to Invest $8.4 Million in Uniontown Hospital's Expansion 2Health News:Super Jake Foundation Hosts 4th Annual 'Heroes Bash' on Nov. 8 to Benefit Pediatric Cancer Research 2Health News:Super Jake Foundation Hosts 4th Annual 'Heroes Bash' on Nov. 8 to Benefit Pediatric Cancer Research 3Health News:Four Medical Centers Awarded Funds to Improve Outcomes Research for Heart Disease and Stroke 2Health News:AMA Congratulates President-Elect Obama 2
(Date:12/4/2009)... , MORRISTOWN, N.J., Dec. 4 /PRNewswire-Fir...PI ), a leading global specialty pharmaceutical co... Laboratories, Inc.-Florida, filed an Abbreviated ... Drug Administration seeking approval to market it... a patent owned by Takeda Pharmaceutical Company L...
(Date:12/4/2009)... , BETHESDA, Md., Dec. 4 Drs....s for prostate-specific antigen (PSA) recurrence f...s of biochemical recurrence rate in a Phase III pi...or injection) or monthly leuprolide in prostate ca... Prostate cancer patients who received FIRMAGON 24...
(Date:12/4/2009)... , WILMINGTON, Del., Dec. 4 /PRNewswire-Firs...ed that the US Food and Drug Administration (FDA) ...ine fumarate) Extended Release Tablets as adjuncti... with Major Depressive Disorder (MDD). SEROQUEL XR...he FDA to treat both major depressive disorder as ...
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Novel K anonymity algorithm safeguards access to data 61811 1Flax and yellow flowers can produce bioethanol 10835 1Flax and yellow flowers can produce bioethanol 10835 2Parents 3A Holiday Safety Tips from Massachusetts Child Injury Lawyer Thomas M Kiley 61808 1Parents 3A Holiday Safety Tips from Massachusetts Child Injury Lawyer Thomas M Kiley 61808 2Parents 3A Holiday Safety Tips from Massachusetts Child Injury Lawyer Thomas M Kiley 61808 3
...06, Demonstrated No Reproductive Toxicity in ... Selected as Clinical Candidate, Demonstrated a 40...ce Daily Oral Dosing -, SAN DIEGO, May 22 Ardea ... preclinical data on its lead non-nucleoside,rever...806, demonstrating,no reproductive toxicity. In ad...
...ull Data Set from the TRIUMPH-1 Trial of Inhaled ...SPRING, Md., May 21 United,Therapeutics Corporati...y,Lung Rx, Inc. today announced that data from sev...nary arterial hypertension (PAH) with treprostinil...TS) meeting in Toronto,Ontario. The ATS presentati...
Other Medicine Technology:Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 2Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 3Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 3Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 5Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 6
...loped over Guidants 20-year history, the VOYAGER R...for successful treatment outcomes. It combines a n...ofile shaft,more flexible markers, and short taper...tortuous anatomy with even greater confidence, ope...
...loped over Guidants 20-year history, the VOYAGER R...for successful treatment outcomes. It combines a n...ofile shaft,more flexible markers, and short taper...tortuous anatomy with even greater confidence, ope...
...loped over Guidants 20-year history, the VOYAGER R...for successful treatment outcomes. It combines a n...ofile shaft,more flexible markers, and short taper...tortuous anatomy with even greater confidence, ope...
AFP EIA Kit
Medicine Products: